trending Market Intelligence /marketintelligence/en/news-insights/trending/K7zFHtUZYTHW23aFHpWlcA2 content esgSubNav
In This List

Hutchison China lung cancer drug shows promise as 2nd-line treatment

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Hutchison China lung cancer drug shows promise as 2nd-line treatment

Hutchison China MediTech Ltd's lung cancer drug savolitinib in combination with AstraZeneca PLC's Tagrisso or Iressa showed preliminary anti-tumor activity in two phase 1b/2 trials on patients whose disease had progressed after a first-line treatment.

The proof-of-concept trials, called TATTON, were conducted on patients with mutation-positive epidermal growth factor receptor non-small cell lung cancer who carry a mutated MET gene.

The common adverse events included nausea and vomiting, among other things, which were consistent with the known safety profiles of each of the three drugs.

Savolitinib is being studied in multiple tumor types worldwide, including kidney, lung and gastric cancers, as a monotherapy and in combination with other targeted and immunotherapy agents.

"MET-amplification impacts a meaningful proportion of patients with EGFRm NSCLC who experience disease progression following treatment with a tyrosine kinase inhibitor in the first or second-line setting. Among patients with this difficult-to-treat resistance mechanism, there is a clear unmet medical need," CEO Christian Hogg said.